Side Effects of Weight Loss Drugs: What Patients Should Know

Weight loss drugs can cause side effects that vary by medication class. GLP-1 and GIP/GLP-1 drugs most often cause nausea, constipation, diarrhea, vomiting, reflux, and reduced appetite. Less common but serious risks include pancreatitis, gallbladder disease, bowel obstruction, dehydration, kidney problems, and allergic reactions 1, 2, 3. A licensed clinician should monitor treatment.

What are the most common side effects of weight loss drugs?

Weight loss drugs most often cause side effects related to how they work. For GLP-1 and GIP/GLP-1 medicines, stomach symptoms are the main issue; for stimulant-based drugs, the heart, sleep, and mood can be more affected 1, 4.

Quick facts: common symptoms, red flags, and who to contact

• Common GLP-1 symptoms include nausea, vomiting, diarrhea, constipation, abdominal pain, reflux, burping, bloating, and reduced appetite 1, 3.
• Phentermine can cause dry mouth, insomnia, fast heart rate, higher blood pressure, nervousness, and constipation because it acts like a stimulant 4.
• Naltrexone-bupropion can cause nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea; it also carries warnings related to mood changes, blood pressure, and seizure risk 5.
• Orlistat blocks some fat absorption, so oily spotting, gas with discharge, urgent stools, and fatty stools are common 6.
• Call the prescribing clinician for side effects that are persistent, worsening, or affecting hydration, nutrition, work, sleep, or daily life.

Why side effects differ by drug class

Different medicines target different body systems. Semaglutide, liraglutide, and tirzepatide change hunger, fullness, insulin, glucagon, and stomach emptying; phentermine stimulates the nervous system; naltrexone-bupropion affects reward and appetite pathways; and orlistat works inside the gut to reduce fat absorption 1, 2, 4, 5, 6.

Why symptoms are often stronger when starting or increasing a dose

GLP-1 side effects often show up during the first weeks or after a dose increase because the gut is adapting to slower stomach emptying and stronger fullness signals. FDA labels for Wegovy and Zepbound use gradual dose escalation schedules to improve gastrointestinal tolerability; Wegovy’s FDA-approved starting dose is 0.25 mg once weekly for 4 weeks before stepwise escalation, and Zepbound’s FDA-approved starting dose is 2.5 mg once weekly for 4 weeks before escalation 1, 2.

Which weight loss medications cause which side effects?

Medication class matters more than the brand name when thinking about side effects. Below are common patterns, but your own risk depends on your health history, dose timing, other medications, and how your body responds.

GLP-1 and GIP/GLP-1 drugs: semaglutide, liraglutide, and tirzepatide

Ozempic (semaglutide, a GLP-1 receptor agonist, FDA-approved for type 2 diabetes), Wegovy (semaglutide, a GLP-1 receptor agonist, FDA-approved for chronic weight management), and Rybelsus (semaglutide, an oral GLP-1 receptor agonist tablet FDA-approved for type 2 diabetes) share the same active ingredient but have different labels and uses 1, 3. Compounded semaglutide via a 503A pharmacy is a compounded GLP-1 receptor agonist variant; it is not FDA-approved, and outcomes data are not FDA-evaluated for compounded formulations.

Mounjaro (tirzepatide, a dual GIP/GLP-1 receptor agonist, FDA-approved for type 2 diabetes) and Zepbound (tirzepatide, a dual GIP/GLP-1 receptor agonist, FDA-approved for chronic weight management) also commonly cause nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, and reflux-type symptoms 2. Compounded tirzepatide via a 503A pharmacy is a compounded dual GIP/GLP-1 receptor agonist variant; it is not FDA-approved, and compounded-formulation outcomes are not established by FDA review.

Saxenda (liraglutide, a GLP-1 receptor agonist, FDA-approved for chronic weight management) and Victoza (liraglutide, a GLP-1 receptor agonist, FDA-approved for type 2 diabetes) are daily injections. Their labels list nausea, diarrhea, constipation, vomiting, injection-site reactions, headache, and low blood sugar risk in some patients, especially when used with insulin or insulin-releasing drugs 11.

Stimulant-based medications: phentermine and phentermine-topiramate

Phentermine is a sympathomimetic appetite suppressant, which means it acts on the nervous system in a stimulant-like way. Phentermine-topiramate is a combination appetite suppressant and anticonvulsant-related weight management medication; the Qsymia label lists paraesthesia, dizziness, altered taste, insomnia, constipation, and dry mouth as common adverse reactions and carries pregnancy-related birth defect warnings 4.

Craving and appetite medications: naltrexone-bupropion

Naltrexone-bupropion is an opioid antagonist and antidepressant combination medication. The Contrave label lists nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea as common adverse reactions, and it includes boxed warnings about suicidal thoughts and behavior related to the bupropion component 5.

Fat-absorption medications: orlistat

Orlistat is a gastrointestinal lipase inhibitor, meaning it reduces absorption of some dietary fat in the gut. The Xenical label lists oily spotting, gas with discharge, fecal urgency, fatty or oily stool, increased bowel movements, and fecal incontinence among common gastrointestinal effects 6.

Why do GLP-1 weight loss drugs cause nausea, constipation, and reflux?

GLP-1 medicines can slow stomach emptying and change fullness signals, so food may sit in the stomach longer. That can help some people feel full sooner, but it can also lead to nausea, bloating, reflux, vomiting, constipation, or diarrhea 1, 12.

How GLP-1 receptor agonists slow stomach emptying

GLP-1 receptor agonists act on receptors in the gut, pancreas, and brain. They increase glucose-dependent insulin release, reduce glucagon, reduce appetite, and delay gastric emptying, which is the movement of food from the stomach into the small intestine 1, 12.

How reduced appetite can change hydration, fiber intake, and bowel habits

When appetite drops, some people also drink less fluid or eat less fiber. Lower food volume, lower fluid intake, and slower gut movement can all make constipation more likely 1, 12.

Why high-fat meals, large portions, and alcohol may worsen symptoms

Large meals, greasy meals, and alcohol can be harder to tolerate when stomach emptying is slower. This is why many clinicians ask patients to notice symptom patterns around meal size, fat content, alcohol, hydration, and dose timing instead of treating nausea as random 15.

What serious side effects should you watch for?

Serious side effects are less common than nausea or constipation, but they matter. Seek prompt care for severe symptoms, especially if you cannot keep fluids down, have severe belly pain, or notice signs of allergy, jaundice, or bowel blockage 1, 2.

Pancreatitis symptoms and when severe abdominal pain needs urgent care

FDA labels for semaglutide and tirzepatide warn about acute pancreatitis. Symptoms can include severe abdominal pain that may radiate to the back and may happen with or without vomiting 1, 2.

Gallstones and gallbladder inflammation after weight loss

Gallbladder problems can happen with GLP-1 medicines and can also happen during weight loss itself. A 2022 systematic review and meta-analysis in JAMA Internal Medicine found GLP-1 receptor agonist use was linked with higher risk of gallbladder or biliary disease, especially at higher doses, longer duration, and when used for weight loss 9.

Severe vomiting, diarrhea, dehydration, and kidney problems

Vomiting or diarrhea can lead to dehydration. FDA labels warn that dehydration from gastrointestinal reactions may worsen kidney function or contribute to acute kidney injury, especially in people with existing kidney disease or other risk factors 1, 2.

Bowel obstruction and gastroparesis warning signs

Delayed stomach emptying is a known GLP-1 effect, and labels have included postmarketing reports of ileus, which is a form of bowel blockage or stopped bowel movement 1, 3. Warning signs include severe belly swelling, ongoing vomiting, inability to pass stool or gas, and severe constipation.

Allergic reactions and emergency symptoms

Serious allergic reactions are uncommon but possible with prescription medicines. Emergency symptoms include trouble breathing, swelling of the face or throat, fainting, or widespread rash with severe symptoms 1, 2.

What are the possible long-term side effects of Ozempic, Wegovy, Mounjaro, and Zepbound?

Long-term safety data are strongest for FDA-approved branded products studied in clinical trials and monitored after approval. For compounded formulations, FDA-evaluated outcomes data are not established, so clinician review and follow-up are important.

What is known from clinical trials and post-marketing safety data

In the STEP 1 trial, adults with overweight or obesity without diabetes received semaglutide 2.4 mg once weekly or placebo with lifestyle intervention for 68 weeks; gastrointestinal symptoms were the most common adverse events, and individual results varied 7. In the SURMOUNT-1 trial, adults with obesity or overweight and weight-related complications received tirzepatide 5 mg, 10 mg, or 15 mg once weekly or placebo for 72 weeks; gastrointestinal adverse events were also the most common and were usually mild to moderate, with individual results varying 8.

What researchers are still studying

Researchers continue to study long-term effects on gallbladder disease, stomach emptying, bowel motility, nutrition, lean mass, mental health signals, and what happens after stopping therapy. Postmarketing reports can detect rare events, but they cannot prove cause by themselves 1, 2, 9.

How long-term monitoring helps manage risk

Monitoring helps a clinician decide whether symptoms are expected, need supportive care, require dose changes, or mean the medication should be stopped. A review may include side effect timing, weight trend, nutrition, hydration, bowel habits, blood sugar risk, kidney history, gallbladder history, and medication interactions.

Why diabetes doses and weight-management doses are not always the same

Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not chronic weight management; Wegovy and Zepbound are FDA-approved for chronic weight management 1, 2, 3. The labeled target doses and goals differ by product, so side effect risk can differ too.

What is “Ozempic face,” and is it caused by the medication?

Ozempic face is a popular term for facial volume loss noticed after weight loss. It is not a formal diagnosis, and it is better understood as a possible effect of fat loss and aging skin rather than a direct, unique drug injury 16.

Why rapid weight loss can change facial fullness

Weight loss can reduce fat in the face as well as the abdomen, hips, and other areas. If weight loss is fast, facial changes may look more noticeable before the skin has time to adapt 16.

Why the term can be misleading

The phrase can make it sound like semaglutide itself targets the face, but the better explanation is overall fat loss. Similar facial changes can happen with weight loss from many causes, including diet, surgery, illness, and other weight loss medications 16.

How gradual weight loss, nutrition, and strength training fit into prevention discussions

A clinician may discuss a steadier pace of weight loss, enough protein, resistance training, sleep, and hydration to support overall health during treatment. These steps cannot guarantee facial fullness, but they can support lean mass and nutrition while weight changes 17.

What happens when you stop taking Ozempic or another GLP-1 drug?

Stopping a GLP-1 can allow appetite and weight to return toward baseline because the medication’s appetite and fullness effects fade. Do not stop, restart, or change dose timing without discussing it with the prescribing clinician.

Why appetite and weight can return after stopping

Obesity is a chronic, relapsing condition for many people, and appetite biology can push the body to regain weight after weight loss. When GLP-1 signaling from medication is removed, hunger, food noise, cravings, and portion size may rise again 10, 13.

What clinical studies suggest about weight regain

In the STEP 1 extension, participants stopped semaglutide 2.4 mg and lifestyle intervention after 68 weeks; during the following year, participants regained about two-thirds of the weight they had lost on average, though individual results varied 10. This does not prove every person will regain weight, but it shows maintenance usually needs a plan.

Why stopping or tapering should be discussed with the prescribing clinician

The right next step depends on why treatment is stopping: side effects, cost, pregnancy planning, surgery, goal weight, or another health issue. A clinician can help weigh risks, review symptoms, and plan follow-up.

Stop or continue decision tree

1. 1If symptoms are mild and short-lived, document timing, meals, hydration, bowel habits, and dose date, then message the prescribing team.
2. 2If symptoms are persistent or limit eating, drinking, sleep, or work, contact the prescribing clinician before the next dose.
3. 3If symptoms include severe belly pain, repeated vomiting, dehydration, jaundice, bowel obstruction signs, fainting, or allergic reaction symptoms, seek urgent or emergency care.
4. 4If you want to stop because you reached a goal or feel well, ask about a maintenance plan before making changes.
5. 5If pregnancy, breastfeeding, surgery, anesthesia, or a new major diagnosis is involved, review the medication plan with the clinician managing that care.

How can patients reduce mild weight loss medication side effects?

Mild side effects may improve with time, meal changes, hydration, and clinician-guided dose adjustments. The safest plan is the one matched to your symptoms, medical history, and current medications.

Eating smaller meals and stopping when full

Smaller meals may be easier to tolerate when stomach emptying is slower. Many clinicians advise patients to stop eating when comfortably full and avoid pushing through fullness, because overeating can worsen nausea, reflux, and vomiting 15.

Hydration, fiber, and constipation support

Constipation can worsen when food and fluid intake fall. A clinician may ask about water intake, fiber, stool frequency, and other constipating medicines before suggesting changes or over-the-counter support.

Protein intake and strength training to help preserve lean mass

Weight loss can include both fat mass and lean mass. Protein intake and resistance training are often discussed during medical weight loss because they support muscle maintenance, function, and metabolic health 17.

When over-the-counter symptom relief may or may not be appropriate

Over-the-counter remedies are not risk-free. Anti-diarrheal medicines, laxatives, antacids, and nausea remedies can interact with health conditions or other prescriptions, so it is best to ask the care team when symptoms are new, severe, or ongoing.

Why dose changes should be clinician-guided

Changing a dose without medical guidance can worsen side effects or reduce treatment safety. FDA labels use stepwise titration schedules because tolerability matters, but your personal plan should come from the prescribing clinician 1, 2.

Who should be cautious or may not qualify for weight loss medication?

Eligibility is based on a full medical review, not only a weight or BMI number. A clinician considers pregnancy status, medical history, current medications, surgery plans, and risk factors before prescribing.

BMI and obesity-related condition criteria commonly used in care

The Endocrine Society guideline supports pharmacotherapy as an adjunct to lifestyle care for adults with BMI of at least 30 kg/m2, or BMI of at least 27 kg/m2 with a weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, or sleep apnea 13. Coverage rules, product labels, and clinician judgment may vary.

Pregnancy, breastfeeding, and reproductive planning

Weight loss medications are generally not used during pregnancy, and several labels include pregnancy warnings or stopping guidance before planned pregnancy 1, 2, 4. People who could become pregnant should discuss contraception, pregnancy plans, and missed periods with their clinician.

History of pancreatitis, gallbladder disease, kidney disease, or severe GI disease

A history of pancreatitis, gallbladder disease, kidney disease, gastroparesis, bowel obstruction, or severe gastrointestinal disease may change the risk-benefit discussion. GLP-1 and GIP/GLP-1 labels include warnings related to pancreatitis, gallbladder disease, kidney injury, severe gastrointestinal adverse reactions, and delayed gastric emptying 1, 2.

Medication interactions and anesthesia or surgery planning

Weight loss medications can interact with other medicines. GLP-1 medicines may raise low blood sugar risk when used with insulin or insulin secretagogues, and delayed stomach emptying can matter for anesthesia planning 1, 2, 14.

Why eligibility is based on a full medical review

Two people with the same BMI can have very different risks. That is why responsible care includes medical history, medication list, allergies, prior side effects, pregnancy status, weight history, and treatment goals before any prescription decision.

Weight loss treatment at Chia: clinician-reviewed semaglutide or tirzepatide options

At Chia, weight loss treatment starts with a 100% online health questionnaire and a licensed US provider review. If treatment is clinically appropriate, medication is compounded by state-licensed US 503A pharmacies and shipped to your door; a prescription is never guaranteed.

How Chia’s online evaluation works

You start with the eligibility quiz, share your health history, current medications, goals, and risk factors, and then a licensed provider reviews your information. Patients can message their care team through the portal between visits.

Compounded semaglutide injection at Chia

Chia offers compounded semaglutide injection, with plans currently starting at $249/mo. Compounded semaglutide is not FDA-approved. Dosing is provider-guided and adjusted over time, including microdosing plans when clinically appropriate.

Compounded tirzepatide tablets or injection at Chia

Chia offers compounded tirzepatide tablets or injection. Compounded tirzepatide is not FDA-approved. Tirzepatide tablet plans currently start at $249/mo, and tirzepatide injection plans currently start at $299/mo; see the product page for up-to-date pricing.

When Chia’s Weight + Energy or Weight + Muscle protocols may be relevant

Some patients ask about broader support while using a GLP-1. Chia’s Weight + Energy protocol includes NAD+ injection plus a choice of GLP-1, and Weight + Muscle includes sermorelin injection plus a choice of GLP-1. NAD+ and sermorelin injections used in these protocols are not FDA-approved for weight loss, energy, or muscle-support goals. These protocols still require provider review and are prescribed only when clinically appropriate.

When should you contact a healthcare professional about side effects?

Contact your clinician when side effects are persistent, worsening, or changing how much you can eat or drink. Seek urgent care for severe symptoms, especially severe belly pain, repeated vomiting, dehydration, jaundice, bowel obstruction symptoms, or allergic reaction symptoms 1, 2.

Symptoms that should be reported promptly

• Nausea, reflux, constipation, or diarrhea that lasts beyond the expected adjustment period or worsens after a dose change.
• Vomiting that prevents normal fluid intake.
• Symptoms of low blood sugar, especially if you use insulin or medicines that increase insulin release 1, 2.
• New right-upper belly pain, fever, yellow skin or eyes, or dark urine.
• Mood changes, insomnia, fast heart rate, or blood pressure changes on stimulant or bupropion-containing medicines 4, 5.

Symptoms that may need urgent or emergency care

Urgent symptoms include severe abdominal pain, pain moving to the back, repeated vomiting, inability to keep fluids down, fainting, confusion, severe constipation with swelling, no stool or gas, trouble breathing, or swelling of the face, lips, tongue, or throat 1, 2.

What to tell your clinician

Share the medication name, dose timing, when symptoms started, recent dose changes, what you ate, alcohol use, hydration, bowel movements, other medications, and any history of pancreatitis, gallbladder disease, kidney disease, or severe GI disease. This helps the clinician decide whether monitoring, symptom support, lab work, dose adjustment, or stopping is safest.

Keep reading

Weight Loss

How to Get Weight Loss Medication: Eligibility, Options, and Costs

Weight Loss Medication

How to Get Weight Loss Drugs: A Step-by-Step Patient Guide

GLP-1 Weight Loss

Side Effects of Weight Loss Injections: What to Expect from GLP-1 Medications